CD4 and neoplasm: The injection of VV-GM alone did not significantly affect Treg cells (CD4+FoxP3+) in tumor infiltrates, but the injection of VV-iPDL1/GM reduced Treg cells to a level lower than that in PBS-treated tumors, resulting in a robustly enhanced CD8+ T cells/Treg ratio (Fig. 5b).